Insulin Therapy and Fatty Liver Disease in Type 2 Diabetes

Introduction to Insulin Resistance and Fatty Liver

• Insulin resistance, not insulin treatment, drives fatty liver development through impaired suppression of lipolysis, increased hepatic de novo lipogenesis, and altered fatty acid metabolism in patients with type 2 diabetes 1, 2

Clinical Implications for Treatment Selection

• The American Diabetes Association recommends GLP-1 receptor agonists or pioglitazone as the preferred glucose-lowering agents for patients with biopsy-proven NASH or high-risk NAFLD with significant fibrosis 3, 4, 5
• Insulin therapy remains the preferred agent for hyperglycemia management in patients with decompensated cirrhosis, according to the American Association of Clinical Endocrinologists 3, 4, 5, 6

Key Clinical Considerations

• Chronic insulin therapy reduces liver fat content and improves hepatic insulin sensitivity in type 2 diabetes patients, as suggested by the European Association for the Study of the Liver 1, 2
• Weight loss of 5-10% through structured lifestyle modification remains the cornerstone of NAFLD treatment, as recommended by the American Heart Association 3, 4